Removal of HDAC-mediated transcriptionalsilencing via HDAC inhibitors may allow activation of PPARγ, as suggested by in vitro and in vivostudies of combined therapy of prostate cancer with HDAC inhibitors and PPARγ agonists [85]. This evidence concerns the gene PPARG and prostate cancer.